CA2415236A1 - Novispirines: peptides antimicrobiens - Google Patents
Novispirines: peptides antimicrobiens Download PDFInfo
- Publication number
- CA2415236A1 CA2415236A1 CA002415236A CA2415236A CA2415236A1 CA 2415236 A1 CA2415236 A1 CA 2415236A1 CA 002415236 A CA002415236 A CA 002415236A CA 2415236 A CA2415236 A CA 2415236A CA 2415236 A1 CA2415236 A1 CA 2415236A1
- Authority
- CA
- Canada
- Prior art keywords
- antimicrobial
- peptide
- ile
- isoleucine
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicinal Preparation (AREA)
Abstract
Les peptides de novispirine sont des agents antimicrobiens avec une activité efficace contre les bactéries Gram négatif. Ces peptides sont non hémolytiques, présentent une cytotoxicité in vivo réduite par rapport à d'autres peptides antimicrobiens, et ils ont été bien tolérés in vivo après une injection intraveineuse. Ces novispirines se lient aussi avec la lipopolysaccharide (LPS), propriété qui peut atténuer les symptômes associés à l'infection par la bactérie Gram négatif. On administre une composition pharmaceutique comprenant de la novispirine comme principe actif à un patient souffrant d'une infection microbienne ou prédisposé à cette infection, et plus particulièrement aux infections par la bactérie Gram négatif.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60685800A | 2000-06-28 | 2000-06-28 | |
US09/606,858 | 2000-06-28 | ||
US09/840,009 | 2001-04-19 | ||
US09/840,009 US6492328B2 (en) | 2000-06-28 | 2001-04-19 | Novispirins: antimicrobial peptides |
PCT/US2001/019094 WO2002000839A2 (fr) | 2000-06-28 | 2001-06-13 | Novispirines: peptides antimicrobiens |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2415236A1 true CA2415236A1 (fr) | 2002-01-03 |
Family
ID=27085347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002415236A Abandoned CA2415236A1 (fr) | 2000-06-28 | 2001-06-13 | Novispirines: peptides antimicrobiens |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1359930A4 (fr) |
JP (1) | JP2004526663A (fr) |
AU (1) | AU2001268421A1 (fr) |
BR (1) | BR0112035A (fr) |
CA (1) | CA2415236A1 (fr) |
IL (1) | IL153556A0 (fr) |
WO (1) | WO2002000839A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7071293B1 (en) * | 1999-08-18 | 2006-07-04 | The University Of Iowa Research Foundation | Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt |
JP2005526092A (ja) * | 2002-03-21 | 2005-09-02 | ケイマン ケミカル カムパニー | 緑内障および眼圧亢進を治療するためのプロスタグランジンF2α類縁体およびそれらの抗菌タンパク質との併用法 |
WO2005092365A2 (fr) * | 2004-03-29 | 2005-10-06 | Novozymes A/S | Utilisation pharmaceutique des novispirines |
US7148404B2 (en) * | 2004-05-04 | 2006-12-12 | Novozymes A/S | Antimicrobial polypeptides |
JP5384948B2 (ja) * | 2007-02-09 | 2014-01-08 | ジェノミディア株式会社 | 新規ポリペプチド及びそれを有効成分として含有する抗菌剤 |
GB201115910D0 (en) | 2011-09-14 | 2011-10-26 | Univ Manchester | Peptides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7470400A (en) * | 1999-08-18 | 2001-03-13 | Regents Of The University Of California, The | Cathelicidin-derived peptides with broad spectrum antimicrobial activity |
-
2001
- 2001-06-13 IL IL15355601A patent/IL153556A0/xx unknown
- 2001-06-13 EP EP01946359A patent/EP1359930A4/fr not_active Withdrawn
- 2001-06-13 JP JP2002505955A patent/JP2004526663A/ja not_active Withdrawn
- 2001-06-13 CA CA002415236A patent/CA2415236A1/fr not_active Abandoned
- 2001-06-13 WO PCT/US2001/019094 patent/WO2002000839A2/fr not_active Application Discontinuation
- 2001-06-13 AU AU2001268421A patent/AU2001268421A1/en not_active Abandoned
- 2001-06-13 BR BRPI0112035-2A patent/BR0112035A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002000839A3 (fr) | 2003-08-28 |
EP1359930A4 (fr) | 2004-07-14 |
IL153556A0 (en) | 2003-07-06 |
WO2002000839A2 (fr) | 2002-01-03 |
JP2004526663A (ja) | 2004-09-02 |
AU2001268421A1 (en) | 2002-01-08 |
EP1359930A2 (fr) | 2003-11-12 |
BR0112035A (pt) | 2006-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6492328B2 (en) | Novispirins: antimicrobial peptides | |
JP5270150B2 (ja) | 細菌感染の治療 | |
JP5969457B2 (ja) | 化合物およびそれらの使用 | |
JP7315724B2 (ja) | リシン置換を含むRomo1由来抗菌ペプチドおよびその変異体 | |
Conlon et al. | Clinical applications of amphibian antimicrobial peptides | |
OA10059A (en) | Compositions and methods for treating infections caused by organisms sensitive to beta-lactam antibiotics | |
Rajasekaran et al. | The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities | |
US20100104552A1 (en) | Antibiotic synergism | |
US7459439B2 (en) | Granulysin peptides and methods of use thereof | |
CA2415236A1 (fr) | Novispirines: peptides antimicrobiens | |
US20050245452A1 (en) | Pharmaceutical use of novispirins | |
Conlon | The potential of frog skin antimicrobial peptides for development into therapeutically valuable anti-infective agents | |
US20100105602A1 (en) | Treatment of intracellular bacterial infections | |
ZA200300374B (en) | Novispirins: Antimicrobial peptides. | |
US8653024B2 (en) | Use of AMPs for treatment of UTI/cystitis | |
US20090253629A1 (en) | Use of defensins against meningitis | |
US20110130326A1 (en) | Defensins for treatment of infective endocarditis | |
JP2005532784A (ja) | 新規の抗菌ボリシンペプチド | |
PL166731B1 (pl) | Sposób wytwarzania środka do leczenia infekcji wywołanych przez organizmy wrażliwe na antybiotykiβ-laktamowe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |